United Therapeutics Corporation (UTHR)
Develops medicines and transplant technologies for patients with rare lung and heart diseases.
$523.63-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+77.9%
The outlook
UTHR is trading near the upper end of its 52-week range with solid analyst support—the consensus leans "Buy" and the average price target sits roughly 27% above the current price. The stock's price trend is mixed relative to its moving averages, suggesting neither strong upward nor downward momentum at the moment. At a trailing P/E of 19.4, valuation appears moderate for a biotech name.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 13 analysts
Price trendMixed vs its moving averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target +27% vs current price
Analyst price target
~12-month · 13 analysts$663.23average target+26.7% vs now
Now $523.63
Low $516.00High $750.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$26.08B
52-wk high
$609.35
52-wk low
$272.12
50-day avg
$548.11
200-day avg
$512.81
Trailing P/E
19.4